Prevalence of oral human papillomavirus by vaccination status among young adults (18–30 years old)

Vaccine

Volumn 35, Issue 27, 2017, Pages 3446-3451

  Hirth, Jacqueline M ^a   Chang, Mihyun ^a   Resto, Vicente A ^a   Guo, Fangjian ^a   Berenson, Abbey B ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

HPV vaccination; Oral cancer; Oral HPV infection; Primary oral cancer prevention

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CHI SQUARE TEST; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEALTH SURVEY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 26; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 40; HUMAN PAPILLOMAVIRUS TYPE 42; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 54; HUMAN PAPILLOMAVIRUS TYPE 55; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE 61; HUMAN PAPILLOMAVIRUS TYPE 62; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 67; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN PAPILLOMAVIRUS TYPE 69; HUMAN PAPILLOMAVIRUS TYPE 70; HUMAN PAPILLOMAVIRUS TYPE 71; HUMAN PAPILLOMAVIRUS TYPE 72; HUMAN PAPILLOMAVIRUS TYPE 73; HUMAN PAPILLOMAVIRUS TYPE 81; HUMAN PAPILLOMAVIRUS TYPE 82; HUMAN PAPILLOMAVIRUS TYPE 83; HUMAN PAPILLOMAVIRUS TYPE 84; HUMAN PAPILLOMAVIRUS TYPE 89; MALE; PAPILLOMAVIRUS INFECTION; POPULATION; PREVALENCE; PRIORITY JOURNAL; PROTECTION; RISK FACTOR; VACCINATION; WART VIRUS; YOUNG ADULT; ADOLESCENT; CLASSIFICATION; GENETICS; ISOLATION AND PURIFICATION; MOUTH; PAPILLOMAVIRIDAE; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MOUTH; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85019889177     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.05.025     Document Type: Article

References (16)

1. Bouvard, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., Ghissassi, F.E., et al. A review of human carcinogens—Part B: biological agents. Lancet Oncol 10 (2009), 321–322.
2. Kreimer, A.R., Clifford, G.M., Boyle, P., Franceschi, S., Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomark Prev 14 (2005), 467–475.
3. Chaturvedi, A.K., Engels, E.A., Anderson, W.F., Gillison, M.L., Incidence trends for human papillomavirus-related and –unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26 (2008), 612–619.
4. Markowitz, L.E., Dunne, E.F., Saraiya, M., Lawson, H.W., Chesson, H., Unger, E.R., Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR 56 (2007), 1–24.
5. Dunne, E.F., Markowitz, L.E., Chesson, H., Curtis, C.R., Saraiya, M., Gee, J., et al. Recommendations on the use of quadrivalent human papillomavirus vaccine in males – advisory committee on immunization practices (ACIP), 2011. MMWR. 60 (2011), 1705–1708.
6. Kreimer, A.R., Prospects for prevention of HPV-driven oropharynx cancer. Oral Oncol 50 (2014), 555–559.
7. Pinto, L.A., Kemp, T.J., Torres, B.N., Isaacs-Soriano, K., Ingles, D., Abrahamsen, M., et al. Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-specific antibodies in the oral cavity: results from the mid-adult male vaccine trial. J Infect Dis 214 (2016), 1276–1283.
8. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. In: Statistics NCfH, editor.
9. Hirth, J.M., Tan, A., Wilkinson, G., Berenson, A., Completion of the human papillomavirus (HPV) vaccine series among males with private insurance between 2006 and 2009. Vaccine 31 (2013), 1138–1140.
10. Gillison, M.L., Broutian, T., Pickard, R.K.L., Z-y, Tong, Xiao, W., Kahle, L., et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA 307 (2012), 693–703.
11. Markowitz, L.E., Hariri, S., Lin, C., Dunne, E.F., Steinau, M., McQuillan, G., et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis 208 (2013), 385–393.
12. Herrero, R., Quint, W., Hildesheim, A., Gonzalez, P., Struijk, L., Katki, H.A., et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE, 8, 2013, e68329.
13. Orosco, R.K., Kedarisetty, S., Hecht, A.S., Chang, D.C., Coffey, C.S., Weissbrod, P.A., Predictors of high-risk and low-risk oral HPV infection in the United States. The Laryngoscope 126 (2016), 1365–1372.
14. Leung, T.F., Liu, A.P.-Y., Lim, F.S., Thollot, F., Oh, H.M.L., Lee, B.W., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial. Human Vaccines Immunother 11 (2015), 1689–1702.
15. Kreimer, A.R., Struyf, F., Del Rosario-Raymundo, M.R., Hildesheim, A., Skinner, S.R., Wacholder, S., et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. The Lancet Oncol 16 (2015), 775–786.
16. Medved Harper, D., Alexander, N.M., Ahern, D.A., Comes, J.C., Smith, M.S., Heutinck, M.A., et al. Women have a preference for their male partner to be HPV vaccinated. PLOS one., 9, 2014, e97119.